Servier Pharmaceuticals shared a post on LinkedIn:
“We’re proud to share that Servier’s therapy for Grade-2 IDH mutant glioma has been nominated for the Prix Galien USA Award in the Best Product for Rare/Orphan Diseases category!
It’s a true privilege to be recognized by The Galien Foundation for our work in delivering innovative treatment options to the glioma community.
Read the full announcement here.”
More posts featuring Servier on OncoDaily.